B
Bo Mu
Researcher at Sichuan University
Publications - 8
Citations - 336
Bo Mu is an academic researcher from Sichuan University. The author has contributed to research in topics: Cancer & Cell growth. The author has an hindex of 7, co-authored 8 publications receiving 290 citations.
Papers
More filters
Journal ArticleDOI
Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model
Yuan Wen,Chun-Ting Wang,Tian-Tai Ma,Zhi-yong Li,Lina Zhou,Bo Mu,Fei Leng,Huashan Shi,Ya-Ou Li,Yuquan Wei +9 more
TL;DR: The results suggest that FAP, a product preferentially expressed by TAF, could function as an effective tumor rejection antigen.
Journal ArticleDOI
Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice.
Huashan Shi,Dan Li,Jing Zhang,Yongsheng Wang,Li Yang,Hailong Zhang,Xianhuo Wang,Bo Mu,Wei Wang,Yu Ma,Fuchun Guo,Yuquan Wei +11 more
TL;DR: The effects of combining shRNA targeting PKM2 and docetaxel on human A549 lung carcinoma cells both in vivo and in vitro suggest that targeting tumor glycolysis can increase the efficacy of chemotherapy.
Journal ArticleDOI
The pigment epithelial-derived factor gene loaded in PLGA nanoparticles for therapy of colon carcinoma.
TL;DR: The inhibitory effect of PEDF-PLGANPs on the growth of CT26s in vitro and in vivo for the first time is demonstrated and could provide an innovative strategy for the therapy of colon carcinoma.
Journal ArticleDOI
Quercetin Liposome Sensitizes Colon Carcinoma to Thermotherapy and Thermochemotherapy in Mice Models
Bing He,Xin Wang,Huashan Shi,Wenjing Xiao,Jing Zhang,Bo Mu,Yong-qiu Mao,Wei Wang,Yongsheng Wang +8 more
TL;DR: The results showed that quercetin liposome inhibited the upregulation of Hsp70 and enhanced apoptosis induced by hyperthermia and thermochemotherapy, indicating that systemic administration of quercetsome can sensitize CT26 cells to thermotherapy and chemothermotherapy.
Journal ArticleDOI
Expression of CD40 and growth-inhibitory activity of CD40 agonist in ovarian carcinoma cells
Yan Zhou,Jing He,Lantu Gou,Bo Mu,Wei-chan Liao,Cong Ma,Ping Tang,Shijie Zhou,Yongjun Zhou,Jinliang Yang +9 more
TL;DR: The results suggest that CD40 is expressed on ovarian carcinoma cells, moreover, that rshCD40L and anti-CD40 agonist antibody have therapeutic potential to inhibit human ovarian cancer growth.